Top Legislation - View All

Latest Action: 07/26/2007 - Sponsor introductory remarks on measure. (CR S10156-10157)

Bill Text
A bill to amend title XVIII of the Social Security Act in order to ensure access to critical medications under the Medicare part D prescription drug program. 7/26/2007--Introduced. Medicare Access to Critical Medications Act of 2007 - Amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act to require prescription drug plan (PDP) formularies to include all or substantially all covered part D drugs in the therapeutic classes: (1) anticonvulsants; (2) antineoplastics; (3) antiretrovirals; (4) antidepressants; (5) antipsychotics; and (6) immunosuppressants.Prohibits the application of a utilization management tool, such as prior authorization or step therapy, to such drugs in certain cases.Prescribes requirements for treatment of such drugs when a determination or reconsideration is requested, as well as the treatment of appeals for such drugs.Establishes data reporting requirements for such drug categories [...]

show full description

Latest Legislation - View All

Latest Action: 07/26/2007 - Sponsor introductory remarks on measure. (CR S10156-10157)

Bill Text
A bill to amend title XVIII of the Social Security Act in order to ensure access to critical medications under the Medicare part D prescription drug program. 7/26/2007--Introduced. Medicare Access to Critical Medications Act of 2007 - Amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act to require prescription drug plan (PDP) formularies to include all or substantially all covered part D drugs in the therapeutic classes: (1) anticonvulsants; (2) antineoplastics; (3) antiretrovirals; (4) antidepressants; (5) antipsychotics; and (6) immunosuppressants.Prohibits the application of a utilization management tool, such as prior authorization or step therapy, to such drugs in certain cases.Prescribes requirements for treatment of such drugs when a determination or reconsideration is requested, as well as the treatment of appeals for such drugs.Establishes data reporting requirements for such drug categories [...]

show full description